Proactive Investors - Run By Investors For Investors

3M Expands Medical-Products Business in Record $4.3 Billion Deal

3M Expands Medical-Products Business in Record $4.3 Billion Deal

Your free daily email from Fuller Treacy Money

Comments of the Day

03 May 2019

 

 

Video commentary for May 2nd 2019

 

 

Eoin Treacy's view

A link to today's video commentary is posted in the Subscriber's Area. 

Some of the topics covered include: correlation between rate cuts and stock market stress, central bank balance sheet and fiscal stimulus indicators, Dollar firm, bonds ease, Wall Street pauses, industrial resources and gold ease further.

 

 

Melting Up Is Hard to Do

 

 

Eoin Treacy's view

A link to the full report is posted in the Subscriber's Area.

It really is all about money supply. The market has priced in the potential for the Fed to announce the imminent end of quantitative tightening instead of the planned September date and when that did not occur profit taking began.

 

 

Central Bank Total Assets and Deficit Spending

 

 

Eoin Treacy's view

I first created the total central bank assets chart in 2014. A couple of years ago I shared the formula with Ben Hunt at Epsilon Capital in a gesture of goodwill following his mention of the size of central bank balance sheets in one of his missives. He subsequently used it and since then the measure has proliferated. I have seen it in a considerable number of investment bank reports, but I have never received a favourable mention for creating it. In future I will be keeping the calculation of indicators proprietary, for the benefit of subscribers.

 

 

3M Expands Medical-Products Business in Record $4.3 Billion Deal

This article by Richard Clough for Bloomberg may be od interest to subscribers. Here is a section:

3M Co. agreed to buy medical-products maker Acelity Inc. for about $4.3 billion, its biggest acquisition ever, as new Chief Executive Officer Mike Roman takes a more aggressive approach to expanding the beleaguered company.

The purchase, from a group of funds advised by Apax Partners, is spurring 3M to scale back share repurchases to conserve cash. 3M will cut buybacks to between $1 billion and $1.5 billion this year from a previous expectation of as much as $4 billion, according to a statement Thursday. The company valued the purchase at $6.7 billion including Acelity’s debt, which was $2.4 billion on Dec. 31.

 

Eoin Treacy's view

Buying back shares has been the go-to strategy for many companies over the last decade because the cost of borrowing has been so low which has made debt more appealing that equity. The practice helps to improve earnings per share, helps investors avoid paying taxes on dividends received and increases the value of shares owned by senior executives. The one thing buybacks do not do is help with creating new products.

 

 

2019: The 50th year of The Chart Seminar

 

 

Eoin Treacy's view

I have had word from the inestimable Mrs. Fuller that the London Philharmonic Orchestra are planning a memorial concert on October 5th at the Royal Festival Hall. It is envisaged that there will be drinks and canapes afterwards. Since this is the 50th year of The Chart Seminar we will be conducting the event on October 3rd and 4th.

I also plan on holding a New York event, potentially in June, and am in discussions with a partner in how best to organise it.

In the meantime, if you have any questions, would like to attend, or have a suggestion for another venue please feel to reach out to Sarah at [email protected].  

The full rate for The Chart Seminar is £1799 + VAT. (Please note US, Australian and Asian delegates, as non-EU residents are not liable for VAT). Annual subscribers are offered a discounted rate of £850. Anyone booking more than one place can also avail of the £850 rate for the second and subsequent delegates.

 

 

Eoin's personal portfolio: precious metal long initiated March 8th

 

 

Eoin Treacy's view

Details of this trade are posted in the Subscriber's Area. 

 

 

 

 

 

 

 

 

The information provided on this website (www.FTMoney.com) is for the purposes of information only.  This website and its content is not and should not be considered or deemed to be an offer of or invitation to engage in any investment activity.  Nothing FT Money does and nothing on this website is intended to operate or be construed as the giving of advice or the making of a recommendation by FT Money to any investor or prospective investor.

FT Money and any other group or associated company of it is not authorised or regulated by the Financial Conduct Authority in the UK or any other regulatory body in any other jurisdiction. 

By means of your login to our service you are deemed to thereby accept our current Terms of Business including this notice,

Except for permission to download a single copy for personal use, the research published by FT Money may not be reproduced, distributed or published in whole or in part by any recipient for any purpose, without the prior express consent of FT Money.

Information featured on the website is based upon information and data provided by FT Money and remains the intellectual property of FT Money.  Some of the information may also be provided by third parties and whilst FT Money will seek to ensure that information featured the website is updated on a regular basis, FT Money does not accept any responsibility for, and disclaims any and all liability for, any such information (including the accuracy of such information) or views or opinions expressed on the website.

Any person considering an investment opportunity as a result of data presented on the website should give full regard to all the content of the website, and should perform their own due diligence and obtain advice from suitably qualified professional advisers before investing.  Prospective investors are also encouraged and recommended to take their own independent legal and taxation advice together with any other advice that they may consider necessary to consider the benefits and risks attached to any investment opportunity.

No representation or warranty, expressed or implied, is or will be made or given by FT Money  (including its executives, employees, agents, contractors and advisors) in relation to the accuracy or completeness of the contents of the website, save that any such liability is not excluded in respect of fraudulent misrepresentation.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use